Related Experiment Video
Updated: May 6, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
6.7K
[Molecular characterization of osteosarcomas]
1Knochentumor-Referenzzentrum am Institut für Pathologie , Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Schweiz, daniel.baumhoer@usb.ch.
Der Pathologe
|November 8, 2013
Summary
Researchers identified a genetic signature for predicting osteosarcoma prognosis at diagnosis. They also found microRNA cluster 17-92 is overexpressed in osteosarcomas, potentially acting as a central regulator in disease development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Osteosarcomas are rare bone cancers with poor prognostic improvement over 30 years.
- Over 30% of osteosarcoma patients have fatal outcomes, necessitating better understanding of molecular tumorigenesis.
- Identification of prognostic/predictive biomarkers and therapeutic targets is urgently needed.
Purpose of the Study:
- To identify a genetic signature for prognostic prediction in osteosarcoma patients at initial diagnosis.
- To investigate the role of microRNA cluster 17-92 in osteosarcoma development.
Main Methods:
- Genome-wide SNP chip analyses were employed to detect genetic signatures.
- Expression levels of microRNA cluster 17-92 in osteosarcomas were analyzed.
Main Results:
- A specific genetic signature was identified, enabling prognostic prediction at the time of initial diagnosis.
- Constitutive overexpression of microRNA cluster 17-92 was observed in osteosarcomas.
- MicroRNA cluster 17-92 is implicated in a network of deregulated oncogenes and tumor suppressors.
Conclusions:
- The identified genetic signature can aid in early prognostic prediction for osteosarcoma patients.
- MicroRNA cluster 17-92 may serve as a central regulator in osteosarcoma development.
- Further research into microRNA cluster 17-92 could reveal novel therapeutic targets.
